Serum levels of LCN2 (p < 0.0001), ELANE (p < 0.01), CAMP (p < 0.05), and CTSG (p < 0.01) were elevated in MS patients, while LTF levels were significantly reduced (p < 0.0001) (Figures 6A–E). Here, CAMP is linked to myeloid sarcoma.